Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
The Lancet. Rheumatology|January 22, 2024
Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
The American Journal of Medicine|January 11, 2005
Mortality in systemic sclerosis: an international meta-analysis of individual patient dataJohn P A Ioannidis, Panayiotis G Vlachoyiannopoulos, Anna-Bettina Haidich, et al.
Clinical and Experimental Rheumatology|September 26, 2025
Circulating microRNAs associated with tumour necrosis factor or fibloblast-like synoviocyte predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE studyYohei Hosokawa, Yusuke Yoshida, Hiroya Tamai, et al.
Annals of the Rheumatic Diseases|January 28, 2025
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
Modern Rheumatology|November 19, 2024
Effectiveness and safety of low-energy shock wave therapy for digital ulcers associated with systemic sclerosis: A Phase 3 pivotal clinical trialTomonori Ishii, Yasushi Kawaguchi, Osamu Ishikawa, et al.
Annals of the Rheumatic Diseases|October 4, 2024
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trialHiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, et al.
Annals of the Rheumatic Diseases|October 21, 2019
Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trialYoshiya Tanaka, Koji Oba, Takao Koike, et al.
Modern Rheumatology|January 7, 2020
2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseasesYoshiya Tanaka, Masataka Kuwana, Takao Fujii, et al.
Arthritis Research & Therapy|April 5, 2025
Discontinuation vs. continuation of concomitant methotrexate in patients with rheumatoid arthritis on certolizumab pegol: results from a randomised, controlled trialShuji Asai, Toshihisa Kojima, Hajime Ishikawa, et al.
International Journal of Rheumatic Diseases|April 14, 2023
Risk factors associated with relapse after methotrexate dose reduction in patients with rheumatoid arthritis receiving golimumab and methotrexate combination therapyNoboru Kitamura, Hitomi Kobayashi, Yosuke Nagasawa, et al.
Pageof 9